Table 1.

Clinical Characteristics of the Patients

	Subject 1	Subject 2	Subject 3	Subject 4	Subject 5
Primary Pathology	Well-differentiated NET, ileal primary	Well-differentiated NET, ileal primary	Well-differentiated NET, pancreatic gastrinoma	Well-differentiated NET, unknown primary	Well-differentiated NET; ileal primary
Symptoms & Biomarkers	Carcinoid Syndrome, elevated serotonin, CgA and pancreastatin	Carcinoid Syndrome, elevated serotonin, CgA and pancreastatin	No symptoms, elevated gastrin	Carcinoid Syndrome, elevated serotonin, CgA and pancreastatin	Carcinoid Syndrome, elevated serotonin, CgA and pancreastatin
Treatment	Octreotide LAR	Octreotide LAR and octreotide SQ; Previous course of everolimus	Octreotide LAR; Previous hepatic chemo- embolization	Octreotide SQ; Previous PRRNT	Octreotide LAR and octreotide SQ

CgA: Chromogranin A SQ: subcutaneous LAR: long-acting release PRRNT: peptide receptor radionuclide therapy